Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical Characteristics, Treatment and Survival Outcomes in Malignant Mesothelioma: Eighteen Years' Experience in Turkey

  • Berk, Serdar (Department of Chest Diseases, Faculty of Medicine, Cumhuriyet University) ;
  • Dogan, Omer Tamer (Department of Chest Diseases, Faculty of Medicine, Cumhuriyet University) ;
  • Kilickap, Saadettin (Department of Medical Oncology, Faculty of Medicine, Cumhuriyet University) ;
  • Epozturk, Kursat (Department of Chest Diseases, Faculty of Medicine, Cumhuriyet University) ;
  • Akkurt, Ibrahim (Department of Chest Diseases, Faculty of Medicine, Cumhuriyet University) ;
  • Seyfikli, Zehra (Department of Chest Diseases, Faculty of Medicine, Cumhuriyet University)
  • Published : 2012.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Malignant mesothelioma (MM) is an insidious tumor with poor prognosis, arising from mesothelial surfaces such as pleura, peritoneum and pericardium. We here aimed to evaluate the demographic, clinical, and radiological features of patients with MM followed in our center as well as their survival. Methods: The study included 228 patients (131 male, 97 female) who were followed up in our institution between 1993 and 2010 with the diagnosis of MM. Results: The mean age was 59.1 years in men and 58.7 years in women and the sex ratio was 1.4:1 in favor of males. Environmental asbestos exposure was present in 86% of the patients for a mean duration of $40{\pm}20$ years (range: 3-70). Pleural effusion and thoracic/abdominal pain were the most common presenting signs and symptoms (70.2% and 57.8%, respectively). One hundred-thirteen (66%) patients were treated with platinum-based combination chemotherapy (PBCT) plus supportive care (SC) and 67 (34%) patients received SC alone. The median follow-up time was 10.0 months. The median overall survival was significantly improved with PBCT plus SC compared to SC alone (11.4 vs. 5.1 months; p=0.005). The 6, 12, 18, and 24-month survival rates were significantly improved with PBCT plus SC compared to SC alone (72%, 43%, 19%, and 2% vs. 49%, 31%, 11%, and 1%). Conclusion: The survival of patients with MM improved in patients treated with PBCT. The survival advantage continued 12- and 24-month after the initial time of combination chemotherapy.

Keywords

References

  1. Adams RF, Gray W, Davies RJ, Gleeson FV (2001). Percutaneous image-guided cutting needle biopsy of the pleura in the diagnosis of malignant mesothelioma. Chest, 120, 1798-802. https://doi.org/10.1378/chest.120.6.1798
  2. Al-Shimemeri AA, Al-Ghadeer HM, Giridhar HR (2003). Diagnostic yield of closed pleural biopsy in exudative pleural effusion. Saudi Med J, 24, 282-6.
  3. Beauchamp HD, Kundra NK, Aranson R, Chong F, MacDonnell KF (1992). The role of closed pleural needle biopsy in the diagnosis of malignant mesothelioma of the pleura. Chest, 102, 1110-2. https://doi.org/10.1378/chest.102.4.1110
  4. Bianchi C, Brollo A, Ramani L, Bianchi T, Giarelli L (2001). Asbestos exposure in malignant mesothelioma of the pleura: a survey of 557 cases. Ind Hlth, 39, 161-7. https://doi.org/10.2486/indhealth.39.161
  5. Bianchi C, Bianchi T (2007). Malignant mesothelioma: global incidence and relationship with asbestos. Ind Hlth, 45, 379-87. https://doi.org/10.2486/indhealth.45.379
  6. Chakrabarti B, Ryland I, Sheard J, Warburton CJ, Earis JE (2006). The role of Abrams percutaneous pleural biopsy in the investigation of exudative pleural effusions. Chest, 129, 1549-55. https://doi.org/10.1378/chest.129.6.1549
  7. Herndon JE, Green MR, Chahinian AP, et al (1998). Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest, 113, 723-31. https://doi.org/10.1378/chest.113.3.723
  8. Hughes RS (2005). Malignant pleural mesothelioma. Am J Med Sci, 329, 29-44. https://doi.org/10.1097/00000441-200501000-00007
  9. Ismail-Khan R, Robinson LA, Williams CC Jr, et al (2006). Malignant pleural mesothelioma: a comprehensive review. Cancer Control, 13, 255-63. https://doi.org/10.1177/107327480601300402
  10. Law MR, Gregor A, Hodson ME, Bloom HJ, Turner-Warwick M (1984). Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients. Thorax, 39, 255-9. https://doi.org/10.1136/thx.39.4.255
  11. Lee CW, Murray N, Anderson H, Rao SC, Bishop W (2009). Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia. Lung Cancer, 64, 308-13. https://doi.org/10.1016/j.lungcan.2008.09.008
  12. Marinaccio A, Binazzi A, Cauzillo G, et al (2007). Analysis of latency time and its determinants in asbestos-related malignant mesothelioma cases of the Italian register. Eur J Cancer, 43, 2722-8. https://doi.org/10.1016/j.ejca.2007.09.018
  13. Metintas M, Hillerdal G, Metintas S (1999). Malignant mesothelioma due to environmental exposure to erionite: follow-up of a Turkish emigrant cohort. Eur Respir J, 13, 523-6. https://doi.org/10.1183/09031936.99.13352399
  14. Metintas M, Hillerdal G, Metintas S, Dumortier P (2010). Endemic malignant mesothelioma: exposure to erionite is more important than genetic factors. Arch Environ Occup Hlth, 65, 86-93. https://doi.org/10.1080/19338240903390305
  15. Moore AJ, Parker RJ, Wiggins J (2008). Malignant mesothelioma. Orphanet J Rare Dis, 3, 34. https://doi.org/10.1186/1750-1172-3-34
  16. MTA (General Directorate of Mineral Research and Exploration). Mineral map of Sivas. http://www.mta.gov.tr/v2.0/turkiye_maden/il_maden/pdf_2010/sivas.pdf [Last accessed in 31.10.2012].
  17. Muers MF, Stephens RJ, Fisher P, et al (2008). Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet, 371, 1685-94. https://doi.org/10.1016/S0140-6736(08)60727-8
  18. Pasetto R, Comba P, Marconi A (2005). Mesothelioma associated with environmental exposures. Med Lav, 96, 330-7.
  19. Pistolessi M, Rusthoven J (2004). A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. Chest, 126, 1318-29. https://doi.org/10.1378/chest.126.4.1318
  20. Rahman NM, Gleeson FV (2008). Image-guided pleural biopsy. Curr Opin Pulm Med, 14, 331-6. https://doi.org/10.1097/MCP.0b013e3282fe9a04
  21. Renshaw AA, Dean BR, Antman KH, Sugarbaker DJ, Cibas ES (1997). The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest, 111, 106-9. https://doi.org/10.1378/chest.111.1.106
  22. Rusch VW, Rosenzweig K, Venkatraman E, et al (2001). A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg, 122, 788-95. https://doi.org/10.1067/mtc.2001.116560
  23. Ruth VS, Baas P, Zoetmulder FA (2003). Surgical treatment of malignant pleural mesothelioma. A review. Chest, 123, 551-61. https://doi.org/10.1378/chest.123.2.551
  24. Scherpereel A, Astoul P, Baas P, et al (2010). Guideline of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J, 35, 479-95. https://doi.org/10.1183/09031936.00063109
  25. Senyigit A, Coskunel M, Topcu F, Isik R, Babayigit C. (2000). Malignant Pleural Mesothelioma: Evaluation of Clinical, Radiological and Histological Features in 136 Cases. Tuberculosis and Thorax, 48, 26-34.
  26. Skammeritz E, Omland LH, Johansen JP, Omland O (2011). Asbestos exposure and survival in malignant mesothelioma: a description of 122 consecutive cases at an occupational clinic. Int J Occup Environ Med, 2, 224-36.
  27. Stahel RA, Weder W, Lievens Y, Felip E; ESMO Guideline Working Group (2010). Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 21, 126-8. https://doi.org/10.1093/annonc/mdp271
  28. Sterman DH, Litzky LA, Albelda SM (2008). Malignant mesothelioma and other primary pleural tumors. In: Fishman AP, Elias JA (eds.) Fishman's Pulmonary Diseases and Disorders, 4th ed. McGraw-Hill, Philadelphia, pp1535-52.
  29. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al (1999). Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg, 117, 54-65. https://doi.org/10.1016/S0022-5223(99)70469-1
  30. van Thiel ER, Surmont VF, van Meerbeeck JP. Malignant pleural mesothelioma: when is radiation therapy indicated? Expert Rev Anticancer Ther, 11, 551-60.
  31. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al (2003). Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol, 21, 2636-44. https://doi.org/10.1200/JCO.2003.11.136
  32. Walters J, Maskell NA (2011). Biopsy techniques for the diagnosis of mesothelioma. Recent Results Cancer Res, 189, 45-5. https://doi.org/10.1007/978-3-642-10862-4_4
  33. Wang ZJ, Reddy GP, Gotway MB, et al (2004). Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET. Radiographics, 24, 105-19. https://doi.org/10.1148/rg.241035058
  34. Yilmaz UM, Utkaner G, Yalniz E, Kumcuoglu Z (1998). Computed tomographic findings of environmental asbestosrelated malignant pleural mesothelioma. Respirology, 3, 33-8. https://doi.org/10.1046/j.1440-1843.1998.00069.x

Cited by

  1. Relationship Between Prognosis and Neutrophil: Lymphocyte and Platelet:Lymphocyte Ratios in Patients with Malignant Pleural Mesotheliomas vol.15, pp.5, 2014, https://doi.org/10.7314/APJCP.2014.15.5.2061
  2. Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study) vol.15, pp.1, 2015, https://doi.org/10.1186/s12885-015-1881-x
  3. Symptom burden in mesothelioma patients admitted to home palliative care vol.32, pp.12, 2016, https://doi.org/10.1080/03007995.2016.1226165
  4. Malignant Pleural Mesothelioma with Bone Marrow Metastases vol.57, pp.17, 2018, https://doi.org/10.2169/internalmedicine.9246-17